Information de reference pour ce titreAccession Number: | 00000816-200809000-00020.
|
Author: | Caselli, Richard J. MD; Chen, Kewei PhD; Lee, Wendy MS; Alexander, Gene E. PhD; Reiman, Eric M. MD
|
Institution: | Departments of Neurology (Dr Caselli), Psychiatry (Drs Chen and Reiman and Ms Lee), and Psychology (Dr Alexander), Mayo Clinic, Scottsdale, Arizona; Banner Alzheimer's Institute and Banner Good Samaritan Medical Center (Drs Chen and Reiman and Ms Lee) and Arizona Alzheimer's Research Consortium (Drs Caselli, Chen, Alexander, and Reiman and Ms Lee), Phoenix, Arizona; and Department of Psychology, University of Arizona, Tucson (Dr Alexander).
|
Title: | |
Source: | Archives of Neurology. 65(9):1231-1236, September 2008.
|
Abstract: | Background: Before symptomatic memory loss, healthy apolipoprotein E [varepsilon]4 (APOE [varepsilon]4) (OMIM 104310) carriers demonstrate accelerated longitudinal decline on memory tests, suggesting the existence of a transitional state between normal aging and mild cognitive impairment (MCI), which we have called amnestic pre-MCI.
Objective: To support our neuropsychological construct of pre-MCI by characterizing and comparing the relationship between measurements of baseline regional hypometabolism and subsequent rates of memory decline in a group of individuals with neuropsychologically defined asymptomatic memory decline (pre-MCI group) and in nondecliners after controlling for APOE [varepsilon]4 gene dose.
Design: Longitudinal study.
Setting: Academic medical center.
Participants: Of 139 healthy individuals in the Arizona APOE Cohort aged 50 to 69 years who underwent longitudinal neuropsychological testing and fludeoxyglucose F 18-positron emission tomography (FDG-PET) since 1994, 10 met our criteria for amnestic pre-MCI, and 15 showed no decline.
Main Outcome Measures: Correlations between lower regional cerebral metabolic rates for glucose (CMRgl) and rates of verbal memory test decline that occurred at a mean of 41 months after baseline FDG-PET using an automated brain mapping algorithm (SPM5).
Results: The pre-MCI and nondecliner groups did not differ in mean (SD) age (56.8 [4.8] years), education (16.5 [2.3] years), sex (19 women [76%]), or APOE [varepsilon]4 carrier status (12 [varepsilon]4 carriers [48%)]. After controlling for APOE [varepsilon]4 gene dose, the pre-MCI group had significant correlations between lower baseline CMRgl in the posterior cingulate, bilateral parietal, and left prefrontal regions (known to be preferentially affected by Alzheimer disease) and subsequent verbal memory decline. Nondecliners had significant correlations bilaterally in the posterior and midcingulate cortices. Correlations in the left parietal, left temporal, and bilateral frontal regions were significantly greater in the pre-MCI group than those in the nondecliner group.
Conclusion: Individuals with amnestic pre-MCI showed significantly greater correlations between cerebral hypometabolism and subsequent long-term memory decline than nondecliners in Alzheimer disease-affected brain regions.
Copyright 2008 by the American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use. American Medical Association, 515 N. State St, Chicago, IL 60610.
|
Author Keywords: | Aging; Alzheimer Disease; Amnesia; Apolipoprotein E4; Brain Diseases, Metabolic; Cingulate Gyrus see Gyrus Cinguli; Cognition Disorders; Fluorodeoxyglucose F18; Glucose Metabolism Disorders; Gyrus Cinguli; Memory Disorders; Positron-Emission Tomography; Prefrontal Cortex.
|
References: | 1. Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. Arch Neurol. 2001;58(12):1985-1992.
2. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256(3):183-194.
3. Morris JC, Storandt M, Miller JP, et al. Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol. 2001;58(3):397-405.
4. Jicha GA, Parisi JE, Dickson DW, et al. Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol. 2006;63(5):674-681.
5. Yaffe K, Petersen RC, Lindquist K, Kramer J, Miller B. Subtype of mild cognitive impairment and progression to dementia and death. Dement Geriatr Cogn Disord. 2006;22(4):312-319.
6. Petersen RC, Thomas RG, Grundman M, et al; Alzheimer's Disease Cooperative Study Group. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005;352(23):2379-2388.
7. Saito Y, Murayama S. Neuropathology of mild cognitive impairment. Neuropathology. 2007;27(6):578-584.
8. Caselli RJ, Reiman EM, Locke DE, et al. Cognitive domain decline in healthy apolipoprotein [varepsilon]4 homozygotes before the diagnosis of mild cognitive impairment. Arch Neurol. 2007;64(9):1306-1311.
9. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261(5123):921-923.
10. Caselli RJ, Reiman EM, Osborne D, et al. Longitudinal changes in cognition and behavior in asymptomatic carriers of the APOE e4 allele. Neurology. 2004;62(11):1990-1995.
11. Lezak MD, Howieson DB, Loring DW. Neuropsychological Assessment. 4th ed. New York, NY: Oxford University Press; 2004.
12. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res. 1990;31(3):545-548.
13. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd ed, revised. Washington, DC: American Psychiatric Association;1987.
14. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34(7):939-944.
15. Chen K, Bandy D, Reiman E, et al. Noninvasive quantification of the cerebral metabolic rate for glucose using positron emission tomography, 18F-fluoro-2-deoxyglucose, the Patlak method, and an image-derived input function. J Cereb Blood Flow Metab. 1998;18(7):716-723.
16. Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med. 1995;36(7):1238-1248.
17. Alexander GE, Chen K, Pietrini P, Rapoport SI, Reiman EM. Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer's disease treatment studies. Am J Psychiatry. 2002;159(5):738-745.
18. Reiman EM, Caselli RJ, Yun LS, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the [varepsilon]4 allele for apolipoprotein E. N Engl J Med. 1996;334(12):752-758.
19. Reiman EM, Caselli RJ, Alexander GE, Chen KW. Tracking the decline in cerebral glucose metabolism in persons and laboratory animals at genetic risk for Alzheimer's disease. Clin Neurosci Res. 2001;1(3):194-206.
20. Reiman EM, Chen KW, Alexander GE, et al. Correlations between apolipoprotein E [varepsilon]4 gene dose and brain-imaging measurements of regional hypometabolism. Proc Natl Acad Sci U S A. 2005;102(23):8299-8302.
21. Talairach J, Tournoux P. Coplanar Stereotaxic Atlas of the Human Brain. New York, NY: Thieme Medical Publishers; 1988.
22. Small GW, Mazziotta JC, Collins MT, et al. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA. 1995;273(12):942-947.
23. Small GW, Ercoli LM, Silverman DHS, et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A. 2000;97(11):6037-6042.
24. de Leon MJ, Mosconi L, Blennow K, et al. Imaging and CSF studies in the preclinical diagnosis of Alzheimer disease. Ann N Y Acad Sci. 2007;1097:114-145.
25. Snowdon DA, Kemper SJ, Mortimer JA, Greiner LH, Wekstein DR, Markesbery WR. Linguistic ability in early life and cognitive function and Alzheimer's disease in late life: findings from the Nun Study. JAMA. 1996;275(7):528-532.
26. Ghebremedhin E, Schultz C, Braak E, Braak H. High frequency of apolipoprotein E [varepsilon]4 allele in young individuals with very mild Alzheimer's disease-related neurofibrillary changes. Exp Neurol. 1998;153(1):152-155.
27. Reiman EM, Chen KW, Alexander GE, et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci U S A. 2004;101(1):284-289.
28. Small BJ, Fratiglioni L, Viitanen M, Winblad B, Backman L. The course of cognitive impairment in preclinical Alzheimer disease: three- and 6-year follow-up of a population-based sample. Arch Neurol. 2000;57(6):839-844.
29. Smith GE, Pankratz VS, Negash S, et al. A plateau in pre-Alzheimer memory decline: evidence for compensatory mechanisms? Neurology. 2007;69(2):133-139.
30. Locke PA, Conneally PM, Tanzi RE, Gusella JF, Haines JL. Apolipoprotein E4 allele and Alzheimer disease: examination of allelic association and effect on age at onset in both early- and late-onset cases. Genet Epidemiol. 1995;12(1):83-92.
31. Tang MX, Maestre G, Tsai WY, et al. Relative risk of Alzheimer disease and age-at-onset distributions based on APOE genotypes among elderly African Americans, Caucasians, and Hispanics in New York City. Am J Hum Genet. 1996;58(3):574-584.
32. Reiman EM, Caselli RJ, Chen KW, Alexander GE, Bandy D, Frost J. Declining brain activity in cognitively normal apolipoprotein E [varepsilon]4 heterozygotes: a foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc Natl Acad Sci U S A. 2001;98(6):3334-3339.
33. Storandt M, Grant EA, Miller JP, Morris JC. Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCI. Neurology. 2006;67(3):467-473.
34. Reisberg B, Prichep L, Mosconi L, et al. The pre-mild cognitive impairment, subjective cognitive impairment stage of Alzheimer's disease. Alzheimers Dement. 2008;4(suppl 1):S98-S108.
|
Language: | English.
|
Document Type: | Original Contribution.
|
Journal Subset: | Clinical Medicine. Behavioral & Social Sciences.
|
ISSN: | 0003-9942
|
NLM Journal Code: | 80k, 0372436
|
Annotation(s) | |
|
|